The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition.
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
13
11
2023
accepted:
15
05
2024
revised:
14
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
epublish
Résumé
Unhealthy lifestyles represent a key element fueling Non-alcoholic fatty liver disease (NAFLD) onset and worsening. We aimed to evaluate the effects of forced acute lifestyle changes on NAFLD evolution. 187 NAFLD patients were followed two years pre- and two years during the lockdown social restrictions in three Italian medical centers. For each patient, biochemical, clinical, non-invasive liver fibrosis, nutritional, and body composition data were collected. An increase in fats and carbohydrate intake associated with impaired weekly physical activity during the lockdown was demonstrated as well as an increase in body mass index and waist-hip-ratio (p < 0.0001 for all). Total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, glucose, insulin, homeostatic model assessment for insulin resistance, and transaminases worsened during the lockdown (glucose: p = 0.0007; p < 0.0001 for the others). Moreover, NAFLD fibrosis score, liver stiffness, and controlled attenuation parameter were also impaired during the same period (p < 0.0001 for all). The bioelectrical impedance analysis (BIA) evidenced an increase of fat mass (FM), and a reduction of free fat mass (FFM) and body cell mass (BCM) (p < 0.0001 for all). The lockdown overall hepatocellular carcinoma (HCC) and Milan-out HCC occurrence revealed Hazard Ratio (HR): 2.398, 95% Confidence Interval (CI):1.16-5, p = 0.02, and HR:5.931, CI:2-17.6, p = 0.008 respectively. A liver disease stage and comorbidities independent association between both the assessed outcomes and body composition analysis in terms of mean values and variation (T1-T2 Δ) was demonstrated. The acute lifestyle changes impacted NAFLD evolution via body composition modifications negatively influencing the HCC occurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Unhealthy lifestyles represent a key element fueling Non-alcoholic fatty liver disease (NAFLD) onset and worsening. We aimed to evaluate the effects of forced acute lifestyle changes on NAFLD evolution.
METHODS
METHODS
187 NAFLD patients were followed two years pre- and two years during the lockdown social restrictions in three Italian medical centers. For each patient, biochemical, clinical, non-invasive liver fibrosis, nutritional, and body composition data were collected.
RESULTS
RESULTS
An increase in fats and carbohydrate intake associated with impaired weekly physical activity during the lockdown was demonstrated as well as an increase in body mass index and waist-hip-ratio (p < 0.0001 for all). Total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, glucose, insulin, homeostatic model assessment for insulin resistance, and transaminases worsened during the lockdown (glucose: p = 0.0007; p < 0.0001 for the others). Moreover, NAFLD fibrosis score, liver stiffness, and controlled attenuation parameter were also impaired during the same period (p < 0.0001 for all). The bioelectrical impedance analysis (BIA) evidenced an increase of fat mass (FM), and a reduction of free fat mass (FFM) and body cell mass (BCM) (p < 0.0001 for all). The lockdown overall hepatocellular carcinoma (HCC) and Milan-out HCC occurrence revealed Hazard Ratio (HR): 2.398, 95% Confidence Interval (CI):1.16-5, p = 0.02, and HR:5.931, CI:2-17.6, p = 0.008 respectively. A liver disease stage and comorbidities independent association between both the assessed outcomes and body composition analysis in terms of mean values and variation (T1-T2 Δ) was demonstrated.
CONCLUSIONS
CONCLUSIONS
The acute lifestyle changes impacted NAFLD evolution via body composition modifications negatively influencing the HCC occurrence.
Identifiants
pubmed: 38802382
doi: 10.1038/s41387-024-00294-2
pii: 10.1038/s41387-024-00294-2
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Informations de copyright
© 2024. The Author(s).
Références
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
pubmed: 28930295
doi: 10.1038/nrgastro.2017.109
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol (Baltim, Md). 2016;64:73–84.
doi: 10.1002/hep.28431
Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl J Med. 2006;354:1264–72.
pubmed: 16554528
doi: 10.1056/NEJMoa054013
Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017;66:323–9.
pubmed: 27599521
doi: 10.1136/gutjnl-2016-311854
Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome. Int J Environ Res Public Health. 2019;16:3415.
pubmed: 31540048
pmcid: 6765902
doi: 10.3390/ijerph16183415
George J, Gish RG, Geier A. MAFLD and cardiovascular events: what does the evidence show? Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2021;19:2025–8.
doi: 10.1016/j.cgh.2021.02.027
Takahara M, Shimomura I. Metabolic syndrome and lifestyle modification. Rev Endocr Metab Disord. 2014;15:317–27.
pubmed: 25263290
doi: 10.1007/s11154-014-9294-8
Peng X, Li J, Zhao H, Lai J, Lin J, Tang S. Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials. BMC Endocr Disord. 2022;22:95.
pubmed: 35399069
pmcid: 8996397
doi: 10.1186/s12902-022-01015-5
Roeb E. Excess body weight and metabolic (Dysfunction)-associated fatty liver disease (MAFLD). Visc Med. 2021;37:273–80.
pubmed: 34540943
pmcid: 8406344
doi: 10.1159/000515445
Taheri E, Bostick RM, Hatami B, Pourhoseingholi MA, Asadzadeh Aghdaei H, Moslem A, et al. Dietary and lifestyle inflammation scores are inversely associated with metabolic-associated fatty liver disease among Iranian adults: a nested case-control study. J Nutr. 2022;152:559–67.
pubmed: 34791370
doi: 10.1093/jn/nxab391
Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2015;63:1229–37.
pubmed: 26385766
doi: 10.1016/j.jhep.2015.07.010
Lim GY, Chang Y, Kim I, Ryu S, Kwon R, Song J. Long working hours and increased risks of lean non-alcoholic fatty liver disease among Korean men and women. Sci Rep. 2023;13:12230.
pubmed: 37507409
pmcid: 10382542
doi: 10.1038/s41598-023-39154-x
Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, et al. Immunity as cornerstone of non-alcoholic fatty liver disease: the contribution of oxidative stress in the disease progression. Int J Mol Sci. 2021;22:436.
pubmed: 33406763
pmcid: 7795122
doi: 10.3390/ijms22010436
Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021;70:2085–95.
pubmed: 33461965
doi: 10.1136/gutjnl-2020-323106
Cheng R, Wang L, Le S, Yang Y, Zhao C, Zhang X, et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease. Nat Commun. 2022;13:2555.
pubmed: 35538056
pmcid: 9091228
doi: 10.1038/s41467-022-29968-0
Ariya M, Koohpayeh F, Ghaemi A, Osati S, Davoodi SH, Razzaz JM, et al. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS ONE. 2021;16:e0249223.
pubmed: 33793621
pmcid: 8016222
doi: 10.1371/journal.pone.0249223
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–78.e5.
pubmed: 25865049
doi: 10.1053/j.gastro.2015.04.005
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol (Baltim, Md). 2018;67:328–57.
doi: 10.1002/hep.29367
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, metabolism, and cardiovascular diseases : NMCD. 2022;32:1-16.
Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol. 2022;13:1087260.
doi: 10.3389/fendo.2022.1087260
Zelber-Sagi S, Bord S, Dror-Lavi G, Smith ML, Towne SD Jr., Buch A, et al. Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients. World J Gastroenterol. 2017;23:1881–90.
pubmed: 28348495
pmcid: 5352930
doi: 10.3748/wjg.v23.i10.1881
Trovato FM, Martines GF, Brischetto D, Catalano D, Musumeci G, Trovato GM. Fatty liver disease and lifestyle in youngsters: diet, food intake frequency, exercise, sleep shortage and fashion. Liver Int : Off J Int Assoc Study Liver. 2016;36:427–33.
doi: 10.1111/liv.12957
The Lancet Infectious D. COVID-19, a pandemic or not? Lancet Infect Dis. 2020;20:383.
doi: 10.1016/S1473-3099(20)30180-8
Santacroce L, Bottalico L, Charitos IA. The impact of COVID-19 on Italy: a lesson for the future. Int J Occup Environ Med. 2020;11:151–2.
pubmed: 32225178
pmcid: 7426732
doi: 10.34172/ijoem.2020.1984
Martinez-Ferran M, de la Guía-Galipienso F, Sanchis-Gomar F, Pareja-Galeano H. Metabolic impacts of confinement during the COVID-19 pandemic due to modified diet and physical activity habits. Nutrients. 2020;12:1549.
pubmed: 32466598
pmcid: 7352228
doi: 10.3390/nu12061549
Fujii H, Nakamura N, Fukumoto S, Kimura T, Nakano A, Nadatani Y, et al. Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction-associated fatty liver disease. Liver Int: Off J Int Assoc Study Liver. 2022;42:995–1004.
doi: 10.1111/liv.15158
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatol. 2018;69:182–236.
Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.
pubmed: 15699287
doi: 10.1161/01.CIR.0000154900.76284.F6
Neovius M, Linné Y, Rossner S. BMI, waist-circumference and waist-hip-ratio as diagnostic tests for fatness in adolescents. Int J Obes (2005). 2005;29:163–9.
doi: 10.1038/sj.ijo.0802867
Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arquivos de gastroenterologia. 2010;47:165–9.
pubmed: 20721461
doi: 10.1590/S0004-28032010000200009
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction (Abingdon, Engl). 1993;88:791–804.
doi: 10.1111/j.1360-0443.1993.tb02093.x
Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatol (Baltim, Md). 2013;57:1182–91.
doi: 10.1002/hep.25993
Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–35.
pubmed: 20870345
doi: 10.1016/j.ultrasmedbio.2010.07.005
Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19:1219–29.
pubmed: 23482703
pmcid: 3587478
doi: 10.3748/wjg.v19.i8.1219
Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver transplantation beyond milan criteria. J Clin Transl Hepatol. 2020;8:69–75.
pubmed: 32274347
pmcid: 7132012
doi: 10.14218/JCTH.2019.00050
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.
pubmed: 35120736
doi: 10.1016/j.jhep.2021.12.022
Dallio M, Romeo M, Gravina AG, Masarone M, Larussa T, Abenavoli L, et al. Nutrigenomics and nutrigenetics in metabolic- (Dysfunction) associated fatty liver disease: novel insights and future perspectives. Nutrients. 2021;13:1679.
pubmed: 34063372
pmcid: 8156164
doi: 10.3390/nu13051679
Kaye AD, Cornett EM, Brondeel KC, Lerner ZI, Knight HE, Erwin A, et al. Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. Best Pract Res Clin Anaesthesiol. 2021;35:269–92.
pubmed: 34511219
doi: 10.1016/j.bpa.2020.12.003
Mazzarella C, Spina A, Dallio M, Gravina AG, Romeo M, DI Mauro M, et al. The analysis of alcohol consumption during the severe acute respiratory syndrome coronavirus 2 Italian lockdown. Minerva medica. 2021.
Zachary Z, Brianna F, Brianna L, Garrett P, Jade W, Alyssa D, et al. Self-quarantine and weight gain related risk factors during the COVID-19 pandemic. Obes Res Clin Pract 2020;14:210–6.
pubmed: 32460966
pmcid: 7241331
doi: 10.1016/j.orcp.2020.05.004
Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2:572–85.
pubmed: 32694793
pmcid: 7325641
doi: 10.1038/s42255-020-0237-2
Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Investig. 2020;50:e13338.
doi: 10.1111/eci.13338
Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann-Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. Endocrinol Diabetes Metab. 2020;4:e00176.
pubmed: 32904932
pmcid: 7460942
doi: 10.1002/edm2.176
Azoulay E, Yackobovitch-Gavan M, Yaacov H, Gilboa I, Lopez A, Sheppes T, et al. Weight status and body composition dynamics in children and adolescents during the COVID-19 pandemic. Front Pediatrics. 2021;9:707773.
doi: 10.3389/fped.2021.707773
Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014;63:2356–68.
pubmed: 24550191
doi: 10.2337/db13-1622
Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, et al. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes care. 2018;41:1732–9.
pubmed: 29844096
pmcid: 7082640
doi: 10.2337/dc18-0071
Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115.
pubmed: 22018588
pmcid: 3214824
doi: 10.1186/1479-5868-8-115
Vall-Roqué H, Andrés A, Saldaña C. The impact of COVID-19 lockdown on social network sites use, body image disturbances and self-esteem among adolescent and young women. Prog neuro-Psychopharmacol Biol psychiatry. 2021;110:110293.
doi: 10.1016/j.pnpbp.2021.110293
Zhu L, Xiao S, Yan X, Zhou S, Yang J, Yuan J. The association between social media use and well-being during quarantine period: testing a moderated mediation model. Front Psychol. 2023;14:1265496.
pubmed: 38023039
pmcid: 10656604
doi: 10.3389/fpsyg.2023.1265496
Kovačić Petrović Z, Peraica T, Kozarić-Kovačić D, Palavra IR. Internet use and internet-based addictive behaviours during coronavirus pandemic. Curr Opin psychiatry. 2022;35:324–31.
pubmed: 35855504
doi: 10.1097/YCO.0000000000000804
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223–38.
pubmed: 33349658
doi: 10.1038/s41575-020-00381-6
Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and monitoring of hepatocellular carcinoma during the COVID-19 pandemic. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2021;19:1520–30.
doi: 10.1016/j.cgh.2020.06.072
Yamamoto T, Imai N, Kuzuya T, Yokoyama S, Yamamoto K, Ito T, et al. Changes in body composition predict the time to treatment failure of lenvatinib in patients with advanced hepatocellular carcinoma: a pilot retrospective study. Nutr Cancer. 2022:1–10.
Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, et al. Rapid depletions of subcutaneous fat mass and skeletal muscle mass predict worse survival in patients with hepatocellular carcinoma treated with sorafenib. Cancers. 2019;11:1206.
pubmed: 31430945
pmcid: 6721466
doi: 10.3390/cancers11081206
Jang HY, Choi GH, Hwang SH, Jang ES, Kim JW, Ahn JM, et al. Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection. Transl Cancer Res. 2021;10:854–66.
pubmed: 35116415
pmcid: 8799077
doi: 10.21037/tcr-20-2974
Lim J, Kim KW, Ko Y, Jang IY, Lee YS, Chung YH, et al. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. BMC Cancer. 2021;21:1164.
pubmed: 34715813
pmcid: 8557070
doi: 10.1186/s12885-021-08905-2